Covis Pharma S.à.r.l.
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Covis Pharma S.à.r.l. sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Covis Pharma S.à.r.l.: 3 sponsored US clinical trials, none currently recruiting.
Covis Pharma S.à.r.l. sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Raynaud's Phenomenon Secondary to Connective Tissue Disease, with 1 trials.
Upper-quartile sponsor footprint
Covis Pharma S.à.r.l. sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
3 total, page 1 of 1
A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients
NCT04377711
Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
NCT02688270
Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)
NCT00458835
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
How the Covis Pharma S.à.r.l. archive is shaped
3 indexed studies, none listed as recruiting (0% open); 3 completed (100%).
Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Raynaud's Phenomenon Secondary to Connective Tissue Disease (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Covis Pharma S.à.r.l.: archived-pipeline peers nationwide
Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Covis Pharma S.à.r.l. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 archived trials
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
- 3EO Health · 0% recruiting · 2 trials
Related
What to do with this Covis Pharma S.à.r.l. page
3 registered trials is a research-attention snapshot, not an endorsement of Covis Pharma S.à.r.l. or any single study.
- None of Covis Pharma S.à.r.l.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Raynaud's Phenomenon Secondary to Connective Tissue Disease is the condition Covis Pharma S.à.r.l. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Raynaud's Phenomenon Secondary to Connective Tissue Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Covis Pharma S.à.r.l. pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.